Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.81 |
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22364998 | 0.94 | BRAF (0.89) | BRAFCYP2C9CSF1R | |
| SCHEMBL3934897 | 0.90 | BRAF (0.82) | BRAFCYP2C9CSF1R | |
| SCHEMBL3943781 | 0.90 | BRAF (0.82) | BRAFCYP2C9CSF1R | |
| SCHEMBL3937762 | 0.90 | BRAF (0.82) | BRAFCYP2C9CSF1R | |
| SCHEMBL3939573 | 0.90 | BRAF (0.81) | BRAFCYP2C9CSF1R | |
| SCHEMBL3934910 | 0.90 | BRAF (0.81) | BRAFCYP2C9CSF1R | |
| SCHEMBL3934396 | 0.89 | BRAF (1.00) | BRAFCYP2C9CSF1R | |
| SCHEMBL3934255 | 0.89 | BRAF (0.83) | BRAFCYP2C9CSF1R | |
| SCHEMBL4011667 | 0.89 | BRAF (0.80) | BRAFCYP2C9CSF1R | |
| SCHEMBL3931650 | 0.89 | BRAF (1.00) | BRAFCYP2C9CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4108248-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | THE JOHNS HOPKINS UNIVERSITY | 2022-12-01 | — | — | US | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2022-04-21 | — | — | US | disclosed |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. | 2021-03-25 | — | — | US | disclosed |
| US-20210038587-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10881646-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2015191610-A2 | COMBINATION THERAPIES USING AGENTS THAT TARGET TUMOR-ASSOCIATED STROMA OR TUMOR CELLS AND OTHER PATHWAYS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015095819-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095829-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014160967-A9 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014160967-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160950-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007183-B2 | Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors | KRAS, BRAF, NRAS | BRAF 2/4885CYP2C9 3618/4885CSF1R 1920/4885 |
| US-10881646-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CYP2C9 4483/4885CSF1R 3809/4885 |
| US-20160045556-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | MKI67, HCCS, NCF1 | BRAF 147/4885CYP2C9 3390/4885CSF1R 2515/4885 |
| US-20220117950-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CYP2C9 4483/4885CSF1R 3809/4885 |
| US-20160221988-A1 | CRYSTALLINE C21H22Cl2N4O2 MALONATE | MAL2, ME1, SLC22A11 | BRAF 1869/4885CYP2C9 368/4885CSF1R 2602/4885 |
| US-20220378852-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | HCCS, MKI67, PBK | BRAF 224/4885CYP2C9 3304/4885CSF1R 2558/4885 |
| US-20210085663-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BRAF, NRAS, KRAS | BRAF 1/4885CYP2C9 4647/4885CSF1R 2384/4885 |
| US-20210038587-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CYP2C9 4483/4885CSF1R 3809/4885 |
| US-11246859-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MAP3K1, MAP3K2, MAP3K6 | BRAF 40/4885CYP2C9 4483/4885CSF1R 3809/4885 |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | BRAF 1621/4885CYP2C9 52/4885CSF1R 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.